Pedro David Delgado-López, Miguel Cárdenas Montes, Jesús Troya García, Beatriz Ocaña-Tienda, Santiago Cepeda, Ricard Martínez Martínez, Eva María Corrales-García
{"title":"神经肿瘤学中的人工智能:方法论基础、实际应用以及伦理和监管问题。","authors":"Pedro David Delgado-López, Miguel Cárdenas Montes, Jesús Troya García, Beatriz Ocaña-Tienda, Santiago Cepeda, Ricard Martínez Martínez, Eva María Corrales-García","doi":"10.1007/s12094-025-03948-4","DOIUrl":null,"url":null,"abstract":"<p><p>Artificial Intelligence (AI) is transforming neuro-oncology by enhancing diagnosis, treatment planning, and prognosis prediction. AI-driven approaches-such as CNNs and deep learning-have improved the detection and classification of brain tumors through advanced imaging techniques and genomic analysis. Explainable AI methods mitigate the \"black box\" problem, promoting model transparency and clinical trust. Mechanistic models complement AI by integrating biological principles, enabling precise tumor growth predictions and treatment response assessments. AI applications also include the creation of digital twins for personalized therapy optimization, virtual clinical trials, and predictive modeling for estimation of tumor resection and pattern of recurrence. However, challenges such as data bias, ethical concerns, and regulatory compliance persist. The European Artificial Intelligence Act and the Health Data Space Regulation impose strict data protection and transparency requirements. This review explores AI's methodological foundations, clinical applications, and ethical challenges in neuro-oncology, emphasizing the need for interdisciplinary collaboration and regulatory adaptation.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Artificial intelligence in neuro-oncology: methodological bases, practical applications and ethical and regulatory issues.\",\"authors\":\"Pedro David Delgado-López, Miguel Cárdenas Montes, Jesús Troya García, Beatriz Ocaña-Tienda, Santiago Cepeda, Ricard Martínez Martínez, Eva María Corrales-García\",\"doi\":\"10.1007/s12094-025-03948-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Artificial Intelligence (AI) is transforming neuro-oncology by enhancing diagnosis, treatment planning, and prognosis prediction. AI-driven approaches-such as CNNs and deep learning-have improved the detection and classification of brain tumors through advanced imaging techniques and genomic analysis. Explainable AI methods mitigate the \\\"black box\\\" problem, promoting model transparency and clinical trust. Mechanistic models complement AI by integrating biological principles, enabling precise tumor growth predictions and treatment response assessments. AI applications also include the creation of digital twins for personalized therapy optimization, virtual clinical trials, and predictive modeling for estimation of tumor resection and pattern of recurrence. However, challenges such as data bias, ethical concerns, and regulatory compliance persist. The European Artificial Intelligence Act and the Health Data Space Regulation impose strict data protection and transparency requirements. This review explores AI's methodological foundations, clinical applications, and ethical challenges in neuro-oncology, emphasizing the need for interdisciplinary collaboration and regulatory adaptation.</p>\",\"PeriodicalId\":50685,\"journal\":{\"name\":\"Clinical & Translational Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-025-03948-4\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03948-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Artificial intelligence in neuro-oncology: methodological bases, practical applications and ethical and regulatory issues.
Artificial Intelligence (AI) is transforming neuro-oncology by enhancing diagnosis, treatment planning, and prognosis prediction. AI-driven approaches-such as CNNs and deep learning-have improved the detection and classification of brain tumors through advanced imaging techniques and genomic analysis. Explainable AI methods mitigate the "black box" problem, promoting model transparency and clinical trust. Mechanistic models complement AI by integrating biological principles, enabling precise tumor growth predictions and treatment response assessments. AI applications also include the creation of digital twins for personalized therapy optimization, virtual clinical trials, and predictive modeling for estimation of tumor resection and pattern of recurrence. However, challenges such as data bias, ethical concerns, and regulatory compliance persist. The European Artificial Intelligence Act and the Health Data Space Regulation impose strict data protection and transparency requirements. This review explores AI's methodological foundations, clinical applications, and ethical challenges in neuro-oncology, emphasizing the need for interdisciplinary collaboration and regulatory adaptation.
期刊介绍:
Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.